Sonnet BioTherapeutics Stock Plummets -74% With 5-Day Losing Streak
Sonnet BioTherapeutics (SONN) stock hit day 5 of a continuous streak of days with losses, with cumulative losses over this period amounting to a -74% return. The company has lost about $14 Mil in value over the last 5 days, with its current market capitalization at about $4.9 Mil. The stock remains 13.7% below its value at the end of 2024. This compares with year-to-date returns of 16.1% for the S&P 500.
Sonnet BioTherapeutics’ recent streak reflects a dramatic identity shift following its merger into Hyperliquid Strategies. The December 2 deal saw SONN shares cease trading, converting to HSI (now PURR) via a five-for-one exchange, transforming the biotech into a digital asset treasury firm and spurring investor exodus.
What is the point? Sustained weakness can be more than noise. It often signals shifting sentiment or deeper concerns. A multi-day losing streak may warn of further downside, or present an opportunity to buy if fundamentals are intact.For quick background, SONN develops a platform for single or bispecific biologic medicines, with a lead candidate targeting non-small cell lung and head and neck cancers using a fully human interleukin 12.
Comparing SONN Stock Returns With The S&P 500
The following table summarizes the return for SONN stock vs. the S&P 500 index over different periods, including the current streak:
| Return Period | SONN | S&P 500 |
|---|---|---|
| 1D | -59.4% | 0.2% |
| 5D (Current Streak) | -74.0% | 1.9% |
| 1M (21D) | -74.9% | -0.2% |
| 3M (63D) | -59.7% | 5.9% |
| YTD 2025 | -13.7% | 16.1% |
| 2024 | -89.5% | 23.3% |
| 2023 | -93.1% | 24.2% |
| 2022 | -80.1% | -19.4% |
Gains and Losses Streaks: S&P 500 Constituents
There are currently 50 S&P constituents with 3 days or more of consecutive gains and 61 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 15 | 37 |
| 4D | 9 | 24 |
| 5D | 13 | 0 |
| 6D | 1 | 0 |
| 7D or more | 12 | 0 |
| Total >=3 D | 50 | 61 |
Key Financials for Sonnet BioTherapeutics (SONN)
Last 2 Fiscal Years:
| Metric | FY2023 | FY2024 |
|---|---|---|
| Revenues | $0.1 Mil | $18,626 |
| Operating Income | $-18.8 Mil | $-11.8 Mil |
| Net Income | $-18.8 Mil | $-7.4 Mil |
Last 2 Fiscal Quarters:
| Metric | 2025 FQ2 | 2025 FQ3 |
|---|---|---|
| Revenues | $0 | $0 |
| Operating Income | $-4.2 Mil | $-3.8 Mil |
| Net Income | $-3.5 Mil | $-3.8 Mil |
The losing streak SONN stock is currently on doesn’t inspire much confidence among investors. In contrast, Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 — the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.